Tekle Pauzaite

5PUBLICATIONS
33CO-AUTHORS
PharmacogenomicsHaematological tumoursEpigenetics (incl. genome methylation and epigenomics)GlycoconjugatesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 27, 2026
Correction: Pauzaite et al. Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway. Biomedicines 2022, 10, 2012.

|Apr 06, 2026
SET1B Drives Sustained HIF Activity and Disease Progression in Clear-Cell Renal Cell Carcinoma.

Brian M Ortmann, Tekle Pauzaite, James A C Bertlin

|Jul 15, 2024
Deubiquitinating enzyme mutagenesis screens identify a USP43-dependent HIF-1 transcriptional response.

Tekle Pauzaite, Niek Wit, Rachel V Seear

|Feb 03, 2023
LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike protein.

Jarrod Shilts, Thomas W M Crozier, Ana Teixeira-Silva

|Aug 26, 2022
Dbf4-Cdc7 (DDK) Inhibitor PHA-767491 Displays Potent Anti-Proliferative Effects via Crosstalk with the CDK2-RB-E2F Pathway.

Tekle Pauzaite, James Tollitt, Betul Sopaci

Pageof 1

Frequent Collaborators

3 joint publications

James A Nathan

2 joint publications

John G Hardy

2 joint publications

Sarah L Allinson

2 joint publications

Nikki A Copeland